Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis : analysis of the KIMS database

Touraine, Philippe ; Sagna, Yempabou ; Mattsson, Anders F. ; Burman, Pia LU ; Van Beek, André P. ; Carlsson, Martin Ove ; Aydin, Ferah ; Feldt-Rasmussen, Ulla and Camacho-Hübner, Cecilia (2022) In Yosetsu Gakkai Shi/Journal of the Japan Welding Society 187(3). p.373-381
Abstract

Objective: To analyze the effectiveness and safety of growth hormone (GH) replacement treatment in adult patients with Langerhans cell histiocytosis (LCH) and GH deficiency (GHD) enrolled in KIMS (Pfizer International Metabolic Database). Patients and methods: Patients with LCH and GHD were studied at baseline and some of them after 1 year of GH treatment. The effectiveness of GH is presented as change after 1 year of treatment (mean, 95% CI). The LCH population was compared to two other groups of patients enrolled in KIMS, granulomatous and lymphocytic hypophysitis. Results: At baseline, 81 adults with LCH (27 with childhood onset, 56% females), mean age at GHD onset of 29 (15) years were studied. Diabetes insipidus was diagnosed in... (More)

Objective: To analyze the effectiveness and safety of growth hormone (GH) replacement treatment in adult patients with Langerhans cell histiocytosis (LCH) and GH deficiency (GHD) enrolled in KIMS (Pfizer International Metabolic Database). Patients and methods: Patients with LCH and GHD were studied at baseline and some of them after 1 year of GH treatment. The effectiveness of GH is presented as change after 1 year of treatment (mean, 95% CI). The LCH population was compared to two other groups of patients enrolled in KIMS, granulomatous and lymphocytic hypophysitis. Results: At baseline, 81 adults with LCH (27 with childhood onset, 56% females), mean age at GHD onset of 29 (15) years were studied. Diabetes insipidus was diagnosed in 86% of patients. Analysis of 1 year of GH treatment was possible in 37 patients. One-year cross-sectional values for the GH dose were 0.39 (S.D. ± 0.21) mg and -0.5 (-1.2 to 0.2) for insulin-like growth factor-1 S.D. Total cholesterol decreased 0.9 (-1.5 to -0.3 (mmol/L); P < 0.05); AGHDA-QoLscore (n = 20) was improved by 2.8 points (-5.6 to 0.0; P < 0.05), while mean BMI increased 0.6 ± 3 kg/m2 (95% CI: -0.2 to 1.4). All these effects did not differ from the two other groups after adjusting for age, gender, and baseline values. In 20 of 77 patients included in the safety analysis, 36 serious adverse events were reported during 435 patient-years (82.8/1000); no new safety signals were reported. Conclusion: After 1 year of GH treatment in patients with LCH, metabolic variables and quality of life improved, with no new safety signals.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Yosetsu Gakkai Shi/Journal of the Japan Welding Society
volume
187
issue
3
pages
9 pages
publisher
Japan Welding Society
external identifiers
  • scopus:85135375980
  • pmid:35830276
ISSN
0021-4787
DOI
10.1530/EJE-22-0160
language
English
LU publication?
yes
id
0ca1408f-3018-4a52-b6f3-f7e173bb2765
date added to LUP
2022-10-07 11:59:42
date last changed
2024-06-13 19:58:46
@article{0ca1408f-3018-4a52-b6f3-f7e173bb2765,
  abstract     = {{<p>Objective: To analyze the effectiveness and safety of growth hormone (GH) replacement treatment in adult patients with Langerhans cell histiocytosis (LCH) and GH deficiency (GHD) enrolled in KIMS (Pfizer International Metabolic Database). Patients and methods: Patients with LCH and GHD were studied at baseline and some of them after 1 year of GH treatment. The effectiveness of GH is presented as change after 1 year of treatment (mean, 95% CI). The LCH population was compared to two other groups of patients enrolled in KIMS, granulomatous and lymphocytic hypophysitis. Results: At baseline, 81 adults with LCH (27 with childhood onset, 56% females), mean age at GHD onset of 29 (15) years were studied. Diabetes insipidus was diagnosed in 86% of patients. Analysis of 1 year of GH treatment was possible in 37 patients. One-year cross-sectional values for the GH dose were 0.39 (S.D. ± 0.21) mg and -0.5 (-1.2 to 0.2) for insulin-like growth factor-1 S.D. Total cholesterol decreased 0.9 (-1.5 to -0.3 (mmol/L); P &lt; 0.05); AGHDA-QoLscore (n = 20) was improved by 2.8 points (-5.6 to 0.0; P &lt; 0.05), while mean BMI increased 0.6 ± 3 kg/m2 (95% CI: -0.2 to 1.4). All these effects did not differ from the two other groups after adjusting for age, gender, and baseline values. In 20 of 77 patients included in the safety analysis, 36 serious adverse events were reported during 435 patient-years (82.8/1000); no new safety signals were reported. Conclusion: After 1 year of GH treatment in patients with LCH, metabolic variables and quality of life improved, with no new safety signals. </p>}},
  author       = {{Touraine, Philippe and Sagna, Yempabou and Mattsson, Anders F. and Burman, Pia and Van Beek, André P. and Carlsson, Martin Ove and Aydin, Ferah and Feldt-Rasmussen, Ulla and Camacho-Hübner, Cecilia}},
  issn         = {{0021-4787}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{373--381}},
  publisher    = {{Japan Welding Society}},
  series       = {{Yosetsu Gakkai Shi/Journal of the Japan Welding Society}},
  title        = {{Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis : analysis of the KIMS database}},
  url          = {{http://dx.doi.org/10.1530/EJE-22-0160}},
  doi          = {{10.1530/EJE-22-0160}},
  volume       = {{187}},
  year         = {{2022}},
}